STOCK TITAN

[144] Rhythm Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhythm Pharmaceuticals, Inc. (RYTM) reported a Form 144 notice for the proposed sale of 16,781 shares of common stock through Morgan Stanley Smith Barney LLC on 09/02/2025, with an indicated aggregate market value of $1,730,960.15 and total shares outstanding listed as 66,420,091. The filing states these shares were acquired on 09/02/2025 via exercise of stock options and paid in cash on the same date.

The filer also disclosed three 10b5-1 sales by Joseph J. Shulman in the past three months: 4,188 shares on 08/21/2025 (gross proceeds $419,090.86), 3,984 shares on 08/11/2025 (gross proceeds $358,891.47), and 7,969 shares on 07/09/2025 (gross proceeds $619,850.56).

Rhythm Pharmaceuticals, Inc. (RYTM) ha segnalato un avviso Form 144 per la vendita proposta di 16.781 azioni ordinarie tramite Morgan Stanley Smith Barney LLC in data 02/09/2025, con un valore di mercato aggregato indicato di $1.730.960,15 e un totale di azioni in circolazione pari a 66.420.091. Il deposito indica che queste azioni sono state acquisite il 02/09/2025 mediante esercizio di opzioni su azioni e pagate in contanti nella stessa data.

Il dichiarante ha inoltre reso noto tre vendite ai sensi della regola 10b5-1 effettuate da Joseph J. Shulman negli ultimi tre mesi: 4.188 azioni il 21/08/2025 (proventi lordi $419.090,86), 3.984 azioni il 11/08/2025 (proventi lordi $358.891,47) e 7.969 azioni il 09/07/2025 (proventi lordi $619.850,56).

Rhythm Pharmaceuticals, Inc. (RYTM) presentó un aviso Form 144 para la venta propuesta de 16.781 acciones ordinarias a través de Morgan Stanley Smith Barney LLC el 02/09/2025, con un valor de mercado agregado indicado de $1.730.960,15 y un total de acciones en circulación de 66.420.091. La presentación indica que estas acciones se adquirieron el 02/09/2025 mediante el ejercicio de opciones sobre acciones y se pagaron en efectivo en la misma fecha.

El declarante también divulgó tres ventas bajo la regla 10b5-1 realizadas por Joseph J. Shulman en los últimos tres meses: 4.188 acciones el 21/08/2025 (ingresos brutos $419.090,86), 3.984 acciones el 11/08/2025 (ingresos brutos $358.891,47) y 7.969 acciones el 09/07/2025 (ingresos brutos $619.850,56).

Rhythm Pharmaceuticals, Inc. (RYTM)는 2025년 09/02일자로 Morgan Stanley Smith Barney LLC를 통해 보통주 16,781주 매도를 제안하는 Form 144 통지를 제출했으며, 표시된 총 시장 가치는 $1,730,960.15이고 총 발행 주식 수는 66,420,091주로 기재되어 있습니다. 해당 제출서에 따르면 이 주식들은 09/02/2025에 스톡옵션 행사로 취득되었고 같은 날 현금으로 지급되었습니다.

신고자는 또한 지난 3개월 동안 Joseph J. Shulman의 10b5-1 계획에 따른 세 건의 매도를 공개했습니다: 4,188주(2025-08-21, 총수익 $419,090.86), 3,984주(2025-08-11, 총수익 $358,891.47), 그리고 7,969주(2025-07-09, 총수익 $619,850.56).

Rhythm Pharmaceuticals, Inc. (RYTM) a déclaré un avis Form 144 pour la vente proposée de 16 781 actions ordinaires via Morgan Stanley Smith Barney LLC le 02/09/2025, avec une valeur de marché agrégée indiquée de $1 730 960,15 et un total d'actions en circulation de 66 420 091. le dépôt indique que ces actions ont été acquises le 02/09/2025 par exercice d'options sur actions et payées en espèces le même jour.

Le déclarant a également divulgué trois ventes au titre de la règle 10b5-1 par Joseph J. Shulman au cours des trois derniers mois : 4 188 actions le 21/08/2025 (produits bruts $419 090,86), 3 984 actions le 11/08/2025 (produits bruts $358 891,47) et 7 969 actions le 09/07/2025 (produits bruts $619 850,56).

Rhythm Pharmaceuticals, Inc. (RYTM) meldete ein Form-144-Anschreiben für den geplanten Verkauf von 16.781 Stammaktien über Morgan Stanley Smith Barney LLC am 02.09.2025, mit einem angegebenen aggregierten Marktwert von $1.730.960,15 und insgesamt 66.420.091 ausstehenden Aktien. Die Einreichung besagt, dass diese Aktien am 02.09.2025 durch Ausübung von Aktienoptionen erworben und am gleichen Tag bar bezahlt wurden.

Der Melder gab außerdem drei 10b5-1-Verkäufe durch Joseph J. Shulman in den letzten drei Monaten bekannt: 4.188 Aktien am 21.08.2025 (Bruttoerlös $419.090,86), 3.984 Aktien am 11.08.2025 (Bruttoerlös $358.891,47) und 7.969 Aktien am 09.07.2025 (Bruttoerlös $619.850,56).

Positive
  • Full disclosure of broker and sale details (Morgan Stanley Smith Barney LLC, NASDAQ listing).
  • Acquisition method disclosed — shares acquired via exercise of stock options and paid in cash on the acquisition date.
  • Prior 10b5-1 sales itemized with dates and gross proceeds, supporting transparency of insider transactions.
Negative
  • None.

Insights

TL;DR: Officer/director-related option exercise followed by a proposed sale and recent scheduled 10b5-1 disposals, indicating planned liquidity events.

The filing documents a same-day option exercise and proposed sale of 16,781 common shares through Morgan Stanley Smith Barney with a stated aggregate market value of $1.73 million against 66.42 million shares outstanding. The transaction type and timing are explicitly reported; the filer discloses prior 10b5-1 sales by Joseph J. Shulman totaling 15,141 shares across July–August 2025 with combined gross proceeds of $1,397,832.89. This information is routine for executive option exercises and Rule 144 notices and provides transparency on insider sales and potential dilution from exercised options.

TL;DR: Transparent compliance filing showing insider exercise and planned sale under Rule 144; no regulatory exceptions or omissions are evident in the text.

The Form 144 lists required broker, share count, and acquisition details, including that the shares were acquired by exercise of stock options and paid in cash. The filer makes the representation concerning absence of undisclosed material adverse information. Prior 10b5-1 sales are separately itemized, which helps segregate planned sales from ad hoc disposals. The document appears procedural and complete for its purpose based on the disclosed fields.

Rhythm Pharmaceuticals, Inc. (RYTM) ha segnalato un avviso Form 144 per la vendita proposta di 16.781 azioni ordinarie tramite Morgan Stanley Smith Barney LLC in data 02/09/2025, con un valore di mercato aggregato indicato di $1.730.960,15 e un totale di azioni in circolazione pari a 66.420.091. Il deposito indica che queste azioni sono state acquisite il 02/09/2025 mediante esercizio di opzioni su azioni e pagate in contanti nella stessa data.

Il dichiarante ha inoltre reso noto tre vendite ai sensi della regola 10b5-1 effettuate da Joseph J. Shulman negli ultimi tre mesi: 4.188 azioni il 21/08/2025 (proventi lordi $419.090,86), 3.984 azioni il 11/08/2025 (proventi lordi $358.891,47) e 7.969 azioni il 09/07/2025 (proventi lordi $619.850,56).

Rhythm Pharmaceuticals, Inc. (RYTM) presentó un aviso Form 144 para la venta propuesta de 16.781 acciones ordinarias a través de Morgan Stanley Smith Barney LLC el 02/09/2025, con un valor de mercado agregado indicado de $1.730.960,15 y un total de acciones en circulación de 66.420.091. La presentación indica que estas acciones se adquirieron el 02/09/2025 mediante el ejercicio de opciones sobre acciones y se pagaron en efectivo en la misma fecha.

El declarante también divulgó tres ventas bajo la regla 10b5-1 realizadas por Joseph J. Shulman en los últimos tres meses: 4.188 acciones el 21/08/2025 (ingresos brutos $419.090,86), 3.984 acciones el 11/08/2025 (ingresos brutos $358.891,47) y 7.969 acciones el 09/07/2025 (ingresos brutos $619.850,56).

Rhythm Pharmaceuticals, Inc. (RYTM)는 2025년 09/02일자로 Morgan Stanley Smith Barney LLC를 통해 보통주 16,781주 매도를 제안하는 Form 144 통지를 제출했으며, 표시된 총 시장 가치는 $1,730,960.15이고 총 발행 주식 수는 66,420,091주로 기재되어 있습니다. 해당 제출서에 따르면 이 주식들은 09/02/2025에 스톡옵션 행사로 취득되었고 같은 날 현금으로 지급되었습니다.

신고자는 또한 지난 3개월 동안 Joseph J. Shulman의 10b5-1 계획에 따른 세 건의 매도를 공개했습니다: 4,188주(2025-08-21, 총수익 $419,090.86), 3,984주(2025-08-11, 총수익 $358,891.47), 그리고 7,969주(2025-07-09, 총수익 $619,850.56).

Rhythm Pharmaceuticals, Inc. (RYTM) a déclaré un avis Form 144 pour la vente proposée de 16 781 actions ordinaires via Morgan Stanley Smith Barney LLC le 02/09/2025, avec une valeur de marché agrégée indiquée de $1 730 960,15 et un total d'actions en circulation de 66 420 091. le dépôt indique que ces actions ont été acquises le 02/09/2025 par exercice d'options sur actions et payées en espèces le même jour.

Le déclarant a également divulgué trois ventes au titre de la règle 10b5-1 par Joseph J. Shulman au cours des trois derniers mois : 4 188 actions le 21/08/2025 (produits bruts $419 090,86), 3 984 actions le 11/08/2025 (produits bruts $358 891,47) et 7 969 actions le 09/07/2025 (produits bruts $619 850,56).

Rhythm Pharmaceuticals, Inc. (RYTM) meldete ein Form-144-Anschreiben für den geplanten Verkauf von 16.781 Stammaktien über Morgan Stanley Smith Barney LLC am 02.09.2025, mit einem angegebenen aggregierten Marktwert von $1.730.960,15 und insgesamt 66.420.091 ausstehenden Aktien. Die Einreichung besagt, dass diese Aktien am 02.09.2025 durch Ausübung von Aktienoptionen erworben und am gleichen Tag bar bezahlt wurden.

Der Melder gab außerdem drei 10b5-1-Verkäufe durch Joseph J. Shulman in den letzten drei Monaten bekannt: 4.188 Aktien am 21.08.2025 (Bruttoerlös $419.090,86), 3.984 Aktien am 11.08.2025 (Bruttoerlös $358.891,47) und 7.969 Aktien am 09.07.2025 (Bruttoerlös $619.850,56).

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What securities are covered by the Form 144 for Rhythm Pharmaceuticals (RYTM)?

The notice covers 16,781 shares of Rhythm Pharmaceuticals common stock proposed to be sold on 09/02/2025.

Who is the broker handling the proposed sale in the RYTM Form 144?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, New York, NY.

How were the 16,781 shares acquired according to the filing?

The filing states the shares were acquired on 09/02/2025 by exercise of stock options and paid in cash on the same date.

What 10b5-1 sales were disclosed for Joseph J. Shulman in the past three months?

Three sales: 7,969 shares on 07/09/2025 (gross $619,850.56), 3,984 on 08/11/2025 (gross $358,891.47), and 4,188 on 08/21/2025 (gross $419,090.86).

What is the aggregate market value and outstanding shares noted in the Form 144?

Aggregate market value is listed as $1,730,960.15 and number of shares outstanding is 66,420,091.
Rhythm Pharmaceu

NASDAQ:RYTM

RYTM Rankings

RYTM Latest News

RYTM Latest SEC Filings

RYTM Stock Data

7.32B
63.31M
0.65%
105.06%
7.48%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON